Conclusion
Nebulised UFH has a strong scientific and biological rationale, and
warrants urgent investigation of its therapeutic potential, for
COVID-19. This investigator-initiated international individual patient
data meta-trial of randomised controlled trials and early phase studies
investigates the efficacy and safety of nebulised UFH, on relevant
outcomes in patients who are hospitalised for COVID-19. Our
pre-specified meta-trial protocol and statistical analysis plan was
prepared before completion of patient recruitment and data collection.
The protocol provides a detailed description of the principles and
methods for analysing and reporting the trial results and is in keeping
with best research practice.